Join to View Full Profile
1190 5th AveNew York, NY 10029
Phone+1 212-241-6756
Fax+1 212-423-0522
Dr. Brody is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joshua Brody is a New York-based oncologist specializing in hematologic oncology. He completed his fellowship in Hematology and Medical Oncology at Stanford University and his residency in Internal Medicine at Yale-New Haven Medical Center. Since 2011, he has served as the Program Director at the Icahn School of Medicine at Mount Sinai. Dr. Brody has published several papers, including studies on immunotherapy and lymphoma, with his work being cited in other publications. He is experienced in conducting clinical trials, investigating treatments such as immunotherapy for COVID-19 and lymphoma.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
Yale-New Haven Medical CenterResidency, Internal Medicine, 2000 - 2003
Stony Brook University Health Sciences Center School of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2003 - Present
NY State Medical License 2012 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Clinical Trials
- Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Start of enrollment: 2011 Feb 01
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Start of enrollment: 2014 Jan 03
Publications & Presentations
PubMed
- 1 citationsmRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.Adam Marks, Sophia Siu, Filippo Bianchini, Chunxi Wang, Ashwitha Lakshmi
Nature Biotechnology. 2026-04-29 - Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in-Mutated Diffuse Large B-Cell Lymphoma.Manik Uppal, Bhavneet Bhinder, Andrew R Marderstein, Connie Lee Batlevi, Lorenzo Falchi
Journal of Clinical Oncology. 2026-04-29 - 2 citationsArmored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.Jaime Mateus-Tique, Ashwitha Lakshmi, Bhavya Singh, Rhea Iyer, Alfonso R Sánchez-Paulete
Cancer Cell. 2026-03-09
Press Mentions
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding From National Cancer InstituteOctober 22nd, 2025- Mount Sinai Researchers Develop First Targeted Therapy for Rare T-cell Lymphoma Following CAR T TreatmentAugust 21st, 2025
- Mount Sinai Researchers Pioneer First Targeted Therapy for Rare T-cell Lymphoma After CAR T TreatmentAugust 21st, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
